Real-world pharmacovigilance analysis of pralatrexate using the FDA adverse event reporting system database
{{output}}
Introduction: Pralatrexate, the first United States Food and Drug Administration (FDA)-approved selective antifolate agent for relapsed/refractory peripheral T cell lymphoma (PTCL), has an incompletely defined postmarketing safet... ...
